Venous thromboembolism (VTE) represents a significant public health concern and is the leading cause of preventable deaths in hospitalized patients. The Agency for Healthcare Research and Quality has identified this topic as a top 10 public safety concern to be addressed.1 As with other VTE investigations, lower extremity deep vein thrombosis (DVT) serves as a surrogate for fatal pulmonary embolism.
Cook K, Napolitano M, Padberg FT. Anti–Factor Xa Assay—A Changing Standard for Venous Thromboprophylaxis?. JAMA Surg. 2016;151(11):1014. doi:10.1001/jamasurg.2016.1851